BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Trials

Exicure Secures Australian Patent for Dual-Target Cancer Therapy Approach

Exicure, Inc. announced that the Australian Patent Office has issued Patent No. 2018388302, titled "GPCR Heteromer Inhibitors and Uses Thereof." ...

March 14, 2025 | News

BioCity Biopharmaceutics and MSD Partner to Evaluate BC3195-KEYTRUDA® Combo in Global Phase 1/2 Trial

BioCity Biopharmaceutics Co., Ltd., a clinical-stage biopharmaceutical company, announced that it has entered into a clinical trial collaboration agr...

March 14, 2025 | News

GC Cell Begins Phase 1 Clinical Trial for CD5 CAR-NK Therapy GCC2005 in T-Cell Lymphomas

GC Cell , under the leadership of CEO Sungyong Won, announced today the initiation of its domestic Phase 1 clinical trial for GCC2005 (AB‑205), a no...

March 13, 2025 | News

Ascletis’ ASC47 Shows Promise as a Long-Acting, Muscle-Preserving Obesity Treatment in Phase Ib Study

ASC47, an adipose-targeted muscle-preserving weight loss drug candidate for the treatment of obesity, demonstrated a half-life of up to 26 days and ...

March 12, 2025 | News

Zhejiang Doer Biologics Completes Phase 2 Enrollment for First-in-Class Tri-Agonist DR10624 in Severe Hypertriglyceridemia

Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and...

March 11, 2025 | News

SPRIM Global Investments and OneIM Launch $300M Joint Venture to Accelerate Clinical Trial Financing

SPRIM Global Investments ("SGI"), a global investment firm specializing in clinical-stage life sciences and pharma services based in Singapore, and On...

March 11, 2025 | News

Gan & Lee Initiates Phase 2 Trial of Bofanglutide, the First GLP-1 Mono-Agonist to Challenge Tirzepatide in Weight Management

Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087) announced that the first participant has been successfully dosed in a P...

March 11, 2025 | News

Fosun Pharma’s Foritinib Secures NMPA Nod for ALK+ NSCLC with Strong CNS Control and Improved Safety

Fosun Pharma announced that the National Medical Products Administration (NMPA) has officially accepted the marketing authorization application for Foritin...

March 10, 2025 | News

AIM Vaccine Secures Clinical Approval for Next-Gen Diploid Rabies Vaccine, Marking a Major Technological Leap

AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement on March 9, 2025, the company's research and development of...

March 10, 2025 | News

RiboX Doses First Patient in Pioneering Circular RNA Therapy Trial for Radiation-Induced Xerostomia

RiboX Therapeutics Ltd. (RiboX), a pioneering biopharmaceutical company, focused on discovering and developing fully engineered circular RNA therapeutics,&...

March 10, 2025 | News

Everest Medicines Doses First Patient with AI-Driven Personalized mRNA Cancer Vaccine EVM16 in Landmark Clinical Trial

The first patient has been dosed with EVM16 at Peking University Cancer Hospital, marking a major milestone as Everest's proprietary AI-based tumor neoan...

March 07, 2025 | News

NEXTBIOMEDICAL’s Nexsphere-F™ Secures FDA Breakthrough Device Designation for Osteoarthritis Pain Treatment

NEXTBIOMEDICAL CO., LTD, a leading developer of cutting-edge Devices, announced that its groundbreaking product 'Nexsphere-F™,' a resorbable microsph...

March 07, 2025 | News

Suvoda Launches AI Assistant ‘Sofia’ to Enhance Clinical Trial Efficiency

Suvoda LLC, a global clinical trial technology company that specializes in complex studies in therapeutic areas like oncology, central nervous system...

March 06, 2025 | News

CStone Pharmaceuticals Advances CS5001 with Phase Ib Trial Application in Australia for First-Line DLBCL Treatment

Phase Ib trial to evaluate CS5001 in combination with R-CHOP as a first-line treatment for diffuse large B-cell lymphoma (DLBCL), aiming to reshape ...

March 06, 2025 | News

Stay Connected